Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenue	$ 42,366	$ 36,671
Cost of goods sold	14,425	9,765
Gross profit	27,941	26,906
Operating expenses:
Research and development	7,846	6,231
Clinical and regulatory affairs	3,884	3,450
Marketing and sales	27,918	19,599
General and administrative	9,946	7,289
Restructuring costs	7,323	0
Settlement costs	4,650	0
Contract termination and business acquisition expenses	4,778	0
Total operating expenses	66,345	36,569
Loss from operations	(38,404)	(9,663)
Other income (expense):
Interest income	62	45
Interest expense	(3,782)	(1,462)
Other income (expense), net	(356)	59
Change in fair value of contingent consideration related to acquisition	0	(100)
Change in fair value of derivative liabilities	(5,088)	0
Total other income (expense)	(9,164)	(1,458)
Net loss before income tax expense	(47,568)	(11,121)
Income tax expense	(103)	(92)
Net loss	(47,671)	(11,213)
Other comprehensive income (loss) foreign currency translation	(105)	(1,754)
Comprehensive loss	$ (47,776)	$ (12,967)
Basic and diluted net loss per share (in shares)	$ (0.62)	$ (0.17)
Shares used in computing basic and diluted net loss per share (in dollars per share)	76,661	67,263